Acute pulmonary oedema: cardiogenic vs non-cardiogenic and emergency treatment
Separates cardiogenic from non-cardiogenic acute pulmonary oedema using the natriuretic peptide (BNP < 100 or NT-proBNP < 300 pg/mL rules out acute heart failure; BNP > 400 or the age-adjusted NT-proBNP of 450, 900 or 1800 pg/mL rules it in), bedside echo and lung ultrasound (LV function, valves, IVC, B-line pattern, effusions), ECG and troponin, the chest X-ray and the history (heart disease, fluids, transfusion within 6 h, sepsis, aspiration, trauma, neurological injury, altitude, airway obstruction, re-expansion, drugs), with PAWP when measured. Cardiogenic oedema is typed as hypertensive (SCAPE, flash oedema), ACS, acute valve or mechanical, arrhythmia, volume overload, TACO or cardiogenic shock, with the ESC CHAMPIT precipitants, the warm/cold and wet/dry profile and the BP class. The emergency lines follow ESC 2021 (2023 update) and ACC/AHA/HFSA 2022: sit up, oxygen only for SpO₂ < 90%, CPAP or BiPAP for respiratory distress, intubation criteria, the first IV loop diuretic dose (20–40 mg furosemide if naïve, 1–2 × the daily oral dose otherwise, with bumetanide and torasemide equivalents), the urine sodium and output check with dose doubling, acetazolamide or a thiazide for resistance, IV nitroglycerin or nitroprusside when SBP > 110 mmHg (not after a PDE5 inhibitor, caution in severe AS), why morphine is not routine, inotropes only for hypoperfusion, and treatment of the cause. Non-cardiogenic oedema and ARDS: P/F severity, lung-protective tidal volume from predicted body weight, prone positioning, conservative fluids and the special causes (TRALI, high altitude, negative-pressure and re-expansion oedema).
| Test | Cardiogenic | Non-cardiogenic (ARDS) |
|---|---|---|
| History | Heart disease, orthopnoea, PND, fluid or salt excess, missed dialysis | Sepsis, pneumonia, aspiration, trauma, pancreatitis, transfusion, drugs |
| Examination | Cool peripheries, S3, raised JVP, peripheral oedema, murmur | Warm peripheries (sepsis), no S3, normal JVP |
| BNP / NT-proBNP | High (BNP > 400, NT-proBNP > 900) | Low (BNP < 100, NT-proBNP < 300) |
| ECG / troponin | Ischaemia, LVH, arrhythmia; rising troponin | Often normal (troponin can rise in sepsis) |
| POCUS echo | Poor LV, dilated LA, severe valve lesion, plethoric IVC | Normal LV and valves, small IVC |
| Lung ultrasound | Diffuse homogeneous bilateral B-lines, smooth pleura, bilateral effusions | Patchy B-lines with spared areas, irregular pleura, sub-pleural consolidation |
| Chest X-ray | Cardiomegaly, upper-lobe diversion, Kerley B, peri-hilar bat-wing, effusions | Peripheral patchy infiltrates, air bronchograms, normal heart size |
| PAWP (if measured) | > 18 mmHg | ≤ 18 mmHg |
| Response to diuretic | Rapid improvement | Little change |
- Oxygen for SpO₂ < 90% or PaO₂ < 60 mmHgIESC 2021
- NIPPV for respiratory distress (RR > 25, SpO₂ < 90%), started as soon as possibleIIaESC 2021
- IV loop diuretics for all patients with fluid overloadIESC 2021
- Loop + thiazide-type diuretic in resistant oedemaIIbESC 2021
- IV vasodilators when SBP > 110 mmHgIIbESC 2021
- Inotropes in SBP < 90 with hypoperfusion; norepinephrine in cardiogenic shockIIbESC 2021
- Routine opiates and routine inotropes not recommendedIIIESC 2021
- Intensive post-discharge GDMT up-titration and early follow-upIESC 2023
- IV loop diuretics promptly for congestion to improve symptoms and reduce morbidity1ACC/AHA 2022
- Inadequate diuresis: higher IV loop dose or a second diuretic (thiazide, acetazolamide, MRA)2aACC/AHA 2022
- IV nitroglycerin or nitroprusside as an adjunct to diuretics without hypotension2bACC/AHA 2022
- Cardiogenic shock: IV inotropes or MCS to maintain perfusion; multidisciplinary shock team1ACC/AHA 2022
- Continue GDMT unless haemodynamically unstable; VTE prophylaxis1ACC/AHA 2022
- McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
- McDonagh TA, Metra M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627-3639.
- Heidenreich PA, Bozkurt B, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure. Circulation 2022;145:e895-e1032.
- Mullens W, Damman K, et al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the ESC. Eur J Heart Fail 2019;21:137-155.
- Felker GM, Lee KL, et al. Diuretic strategies in patients with acute decompensated heart failure (DOSE). N Engl J Med 2011;364:797-805.
- Mullens W, Dauw J, et al. Acetazolamide in acute decompensated heart failure with volume overload (ADVOR). N Engl J Med 2022;387:1185-1195.
- Trullàs JC, Morales-Rull JL, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 2023;44:411-421.
- Gray A, Goodacre S, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema (3CPO). N Engl J Med 2008;359:142-151.
- Januzzi JL, van Kimmenade R, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients (ICON). Eur Heart J 2006;27:330-337.
- Mebazaa A, Yilmaz MB, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the HFA, EuSEM and SAEM. Eur J Heart Fail 2015;17:544-558.
- Matthay MA, Arabi Y, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med 2024;209:37-47.
- Grasselli G, Calfee CS, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 2023;49:727-759.
- Guérin C, Reignier J, et al. Prone positioning in severe acute respiratory distress syndrome (PROSEVA). N Engl J Med 2013;368:2159-2168.
- Mebazaa A, Davison B, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). Lancet 2022;400:1938-1952.